{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.631","value":"1.70"},{"groupId":"OG001","spread":"2.88","value":"4.63"},{"groupId":"OG002","spread":"0.0566","value":"4.10"},{"comment":"Number of participants analyzed was less than 3, thus standard deviation was not calculated.","groupId":"OG003","spread":"NA","value":"9.15"},{"groupId":"OG004","spread":"1.59","value":"12.7"},{"groupId":"OG005","spread":"4.61","value":"12.7"},{"groupId":"OG006","spread":"3.42","value":"12.1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"2"},{"groupId":"OG004","value":"3"},{"groupId":"OG005","value":"3"},{"groupId":"OG006","value":"5"}],"units":"Participants"}],"dispersionType":"Standard Deviation","groups":[{"description":"CP-751,871 0.2 mg/kg administered intravenously on Day 1 of Cycle 1 (4 weeks or 8 weeks), and dose of 50% from the Cycle 1 dose administered on Day 1 of subsequent cycles, starting from Cycle 2 (4 weeks)","id":"OG000","title":"CP-751,871 0.2 mg/kg"},{"description":"CP-751,871 0.4 mg/kg administered intravenously on Day 1 of Cycle 1 (4 weeks or 8 weeks), and dose of 50% from the Cycle 1 dose administered on Day 1 of subsequent cycles, starting from Cycle 2 (4 weeks)","id":"OG001","title":"CP-751,871 0.4 mg/kg"},{"description":"CP-751,871 0.8 mg/kg administered intravenously on Day 1 of Cycle 1 (4 weeks or 8 weeks), and dose of 50% from the Cycle 1 dose administered on Day 1 of subsequent cycles, starting from Cycle 2 (4 weeks)","id":"OG002","title":"CP-751,871 0.8 mg/kg"},{"description":"CP-751,871 1.5 mg/kg administered intravenously on Day 1 of Cycle 1 (4 weeks or 8 weeks), and dose of 50% from the Cycle 1 dose administered on Day 1 of subsequent cycles, starting from Cycle 2 (4 weeks)","id":"OG003","title":"CP-751,871 1.5 mg/kg"},{"description":"CP-751,871 3 mg/kg administered intravenously on Day 1 of Cycle 1 (4 weeks or 8 weeks), and dose of 50% from the Cycle 1 dose administered on Day 1 of subsequent Cycles, starting from Cycle 2 (4 weeks)","id":"OG004","title":"CP-751,871 3 mg/kg"},{"description":"CP-751,871 6 mg/kg administered intravenously on Day 1 of Cycle 1 (4 weeks or 8 weeks), and dose of 50% from the Cycle 1 dose administered on Day 1 of subsequent cycles, starting from Cycle 2 (4 weeks)","id":"OG005","title":"CP-751,871 6 mg/kg"},{"description":"CP-751,871 10 mg/kg administered intravenously on Day 1 of Cycle 1 (4 weeks or 8 weeks) and subsequent cycles, starting from Cycle 2 (4 weeks)","id":"OG006","title":"CP-751,871 10 mg/kg"}],"paramType":"MEAN","populationDescription":"All participants treated who had at least 1 of the PK parameters of primary interest.","reportingStatus":"POSTED","timeFrame":"Cycle 1: predose; 1; 24; 48; 72; 168; 336; 504 and 672 and 1008 (for participants with an up to 8-week Cycle 1 only) hours postdose","title":"Single Dose Plasma Decay Half-life (t1/2) for CP-751,871","type":"SECONDARY","unitOfMeasure":"days"}